Solid Biosciences (SLDB) stock surges after strong Phase 1/2 data for its Duchenne therapy SGT-003. Read more here.

Muscular dystrophy is a disease caused by a genetic mutation. The muscles of muscular dystrophy patients weaken.. | Genetics And Genomics ...

Solid Biosciences' SGT-003 gene therapy showed strong dystrophin expression, muscle health improvements, and no serious safety concerns in early trial data.

The company raised $200 million after early findings hinted its therapy could be more potent than others like it, including ...

Duchenne muscular dystrophy (DMD) is a rare hereditary disease that is associated with progressive muscle wasting. The ...

Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...

Ezutromid was designed to treat DMD by boosting utrophin levels to compensate for the faulty dystrophin protein that is the root cause of the very rare muscle-wasting disease. Summit reported ...

Utrophin increase in muscle cells after transcriptional adaptation normalises cell function in Duchenne muscular dystrophy ...

Week in brief provides you an up to date collection of the latest developments in the world of genomics and omics.

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) released topline results from its Phase 2 FIGHT DMD trial. The study evaluated ...